Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor

doi:10.19401/j.cnki.1007-3639.2021.07.011

China Oncology ›› 2021, Vol. 31 ›› Issue (7): 640-646.doi: 10.19401/j.cnki.1007-3639.2021.07.011

• Review • Previous Articles Next Articles

Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor

LI Wei, ZHANG Shanling, TAO Yingjie, WANG Xudong

Maxillofacial and ENT Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

Online:2021-07-30 Published:2021-08-04
Contact: WANG Xudong E-mail: dr_xdwang@126.com

Abstract

Abstract: Cancer immunotherapy based on immune checkpoint inhibitor (ICI) has been widely developed. However, due to the low objective response rate of ICI monotherapy, only 10%-20% in some tumors, ICI combination therapy has become a research highlight recently. Studies have shown that cancer metabolism and its products can regulate the differentiation and function of T cells. Regulating cell metabolism can prolong the longevity and enhance the function of T cells in the tumor microenvironment (TME), and the combination of ICI can improve its therapeutic effect. Here, we summarized the differentiation of T cells regulated by immune metabolism, the effects of TME and ICI on T cell immune metabolism, and research progresses on the role of combination of cell metabolism drugs and ICI in cancer immunotherapy.

Key words: T lymphocytes, Immune metabolism, Immune checkpoint inhibitor, Tumor microenvironment, Combination therapy

LI Wei, ZHANG Shanling, TAO Yingjie, WANG Xudong. Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor[J]. China Oncology, 2021, 31(7): 640-646.

[1]	ZHANG Jun , DONG Yuhua , YANG Ye , ZHANG Mengqi , HE Chang . A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma [J]. China Oncology, 2021, 31(4): 294-301.
[2]	HAN Xiangchen, LI Xiaoguang, HU Xin. Single-cell RNA sequencing and its application in breast cancer [J]. China Oncology, 2021, 31(11): 1110-1114.
[3]	JIANG Mengyi , LU Yanqiao , WANG Hongxia . Research progress and clinical significance of breast cancer heterogeneity [J]. China Oncology, 2020, 30(5): 394-400.
[4]	LU Xunxi, GUO Linwei, LI Xiaoguang, HU Xin. Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer [J]. China Oncology, 2020, 30(2): 154-160.
[5]	FAN Shouren , WU Shuhua , LI Yangyang , XU Xiaoyang , HE Shuang , WEN Feifei , LIU Liu , GUO Ningjie , JIA Zhenzhen . The correlation between LC3 and tumor-associated macrophages in colorectal cancer and its clinical significance [J]. China Oncology, 2020, 30(11): 849-857.
[6]	WANG Jie . Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer [J]. China Oncology, 2020, 30(10): 744-749.
[7]	FANG Yujia, ZHOU Juan, SU Chunxia. Immune microenvironment for liver metastasis of non-small cell lung cancer and future intervention strategies [J]. China Oncology, 2020, 30(10): 750-758.
[8]	JIN Yujuan, HU Liang, JI Hongbin. Advances in molecular mechanism of lung cancer: from rational to practice [J]. China Oncology, 2020, 30(10): 759-769.
[9]	LI Yuan. Personalized immunotherapy for lung cancer under the guidance of pathology [J]. China Oncology, 2020, 30(10): 770-776.
[10]	YANG Lingge, WANG Chunmeng. Drug therapy for alveolar soft part sarcoma: current status and progress [J]. China Oncology, 2019, 29(9): 746-752.
[11]	YANG Yunsong, JIANG Yizhou, HU Xin, SHAO Zhimin. Research progress of breast tumor microenvironment-targeted therapy [J]. China Oncology, 2019, 29(12): 977-984.
[12]	ZHANG Quan, QIU Sifang, ZHAO Kui, et al. Subsets and clinical significance of CD4⁺, CD8⁺and CD28⁺ T lymphocytes in the patients with colorectal carcinoma and adenoma [J]. China Oncology, 2018, 28(8): 577-583.
[13]	GUO Ye. The immunotherapy for head and neck cancer [J]. China Oncology, 2017, 27(6): 459-462.
[14]	CAO Dalong, YE Dingwei. Advances in immunotherapy for metastatic renal cancer [J]. China Oncology, 2017, 27(10): 829-832.
[15]	CAI Ming, YANG Dejuan, HU Feixiang, et al. Scheduling of chemotherapy based on direct monitoring of pO2 in tumor microenvironment by EPR oximetry [J]. China Oncology, 2016, 26(7): 589-595.

Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments